Randomized Clinical Trials in Pancreatic Adenocarcinoma

被引：3

作者：

Rudloff, Udo ^{[1
]}

Maker, Ajay V. ^{[1
]}

Brennan, Murray F. ^{[1
]}

Allen, Peter J. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Hepatopancreaticobiliary Serv, New York, NY 10021 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2010年 / 19卷 / 01期

关键词：

Pancreas cancer; Randomized controlled trials; Literature review; Level la evidence; PHASE-III TRIAL; MALIGNANT BILIARY OBSTRUCTION; EXTENDED RETROPERITONEAL LYMPHADENECTOMY; QUALITY-OF-LIFE; COOPERATIVE-ONCOLOGY-GROUP; PYLORUS-PRESERVING PANCREATICODUODENECTOMY; COMPARING STANDARD PANCREATICODUODENECTOMY; UNRESECTABLE PERIAMPULLARY CANCER; UPPER GASTROINTESTINAL MALIGNANCY; TOTAL PARENTERAL-NUTRITION;

D O I：

10.1016/j.soc.2009.09.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This article critically reviews and ranks 107 prospective, randomized controlled trials (ACT) for pancreatic adenocarcinoma published between 2000 and 2008 identified through a standard MEDLINE literature search strategy, according to a standardized, previously published 3-tiered system (la, lb, and lc). All trials included in this article are la or lb. Types of treatment reviewed include surgery, chemotherapy, molecular therapy, radiation therapy, immunotherapy, and palliative therapy.

引用

页码：115 / +

页数：37

共 50 条

[1] Randomized Clinical Trials in Pancreatic Cancer
Goel, Neha
Reddy, Sanjay S.
[J]. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 26 (04) : 767 - 790
[2] Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC)
Andre Alabd
Andrew Alabd
Oloruntoba Bolaji
Kavin Sugumar
John Ammori
Jeffrey Hardacre
Jordan M. Winter
[J]. Annals of Surgical Oncology, 2021, 28 : 1060 - 1068
[3] Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC)
Alabd, Andre
Alabd, Andrew
Bolaji, Oloruntoba
Sugumar, Kavin
Ammori, John
Hardacre, Jeffrey
Winter, Jordan M.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (02) : 1060 - 1068
[4] TRIALS AND TRIBULATIONS: DIVERSITY AND INCLUSION IN PANCREATIC DUCTAL ADENOCARCINOMA CLINICAL TRIALS
Herremans, Kelly M.
Riner, Andrea N.
Hughes, Steven J.
Trevino, Jose G.
[J]. GASTROENTEROLOGY, 2021, 160 (06) : S903 - S903
[5] Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
Paniccia, Alessandro
Merkow, Justin
Edil, Barish H.
Zhu, Yuwen
[J]. CHINESE JOURNAL OF CANCER RESEARCH, 2015, 27 (04) : 376 - 391
[6] Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
Alessandro Paniccia
Justin Merkow
Barish H.Edil
Yuwen Zhu
[J]. Chinese Journal of Cancer Research, 2015, 27 (04) : 376 - 391
[7] Elucidating the Causes of Improved Survival in Recent Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials
Alabd, A.
Bolaji, O.
Ammori, J.
Hardacre, J.
Winter, J.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S136 - S137
[8] Examination of External Validity in Randomized Controlled Trials for Adjuvant Treatment of Pancreatic Adenocarcinoma
Sorg, Carolin
Schmidt, Jan
Buechler, Markus W.
Edler, Lutz
Maerten, Angela
[J]. PANCREAS, 2009, 38 (05) : 542 - 550
[9] Clinical trials to reduce pancreatic fistula after pancreatic surgery-review of randomized controlled trials
Kitahata, Yuji
Kawai, Manabu
Yamaue, Hiroki
[J]. TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 1
[10] Pancreatic Adenocarcinoma Invasiveness and the Tumor Microenvironment: From Biology to Clinical Trials
Mejia, Isabel
Bodapati, Sandhya
Chen, Kathryn T.
Diaz, Begona
[J]. BIOMEDICINES, 2020, 8 (10) : 1 - 32

← 1 2 3 4 5 →